AZN - AstraZeneca breast cancer therapy fails in late-stage trial
2024-06-18 07:05:27 ET
More on AstraZeneca
- AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade)
- AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath
- AstraZeneca: A Triple Shot Of Income, Growth, And Value
- AstraZeneca gets FDA okay for Imfinzi for endometrial cancer
- AstraZeneca's Farxiga approved for type 2 diabetes for children as young as 10